Martončíková M., Orendáčová J., Račeková E.:
Clinical Importance of Testing Olfactory
Functions for Early Detection of Neurodegenerative Diseases
|
3 |
Bronský J., Chada M., Kotaška K., Průša R.:
Hypothalamic Neuropeptides Involved in
Food Intake and Regulation of Energy Homeostasis
|
8 |
Tichý J.:
Subarachnoid Haemorrhage – Findings in Cerebrospinal Fluid, in Particular
the Glucose Level
|
14 |
Brázdil M.1, Dobšík M.1,2, Pažourková M.3, Krupa P.3, Rektor I.1:
Importance of Functional MRI
for Evaluation of Cognitive Processes in the Human Brain. Localization of Neuronal
Populations Activated by „Oddball“ Task
|
20 |
Tichá V., Havrdová E., Nováková I., Horáková D.:
Mitoxanthrone in the Treatment of
Active Multiple Sclerosis (MS)
|
31 |
Peterová V.1, Dostál C.2, Linková L.2, Seidl Z.1, Olejárová M.2, Havrdová E.3, Zvárová J.4, Zvára K.5, Viták T.1, Tichá V.3, Daneš J.1:
Differences between Supratentorial MR Foci in the Brain
of Patiens with Neuropsychiatric Lupus and Multiple Sclerosis
|
38 |
Lásiková Š.1, Moravcová L.1, Pícha D.1, Žďárský E.2:
Dynamics of the Polymerase Chain
Reaction (PCR) and its Value in Lyme Borreliosis
|
44 |
Herzig R.1, Vlachová I.1, Urbánek K.1, Křupka B.1, Gabryš M.2, Mareš J.1, Šaňák D.1,Schneiderka P.3, Buřval S.4:
Incidence of Modifiable Risk Factors of Spontaneous Intracerebral and
Subarachnoid Haemorrhages in the Olomouc Region. Prospective Study 1998–2000.
Part I.: Metabolic Risk Factors
|
50 |
Dbalý V.1,8, Tovaryš F.1, Honová H.2, Petruželka L.2, Prokeš K.2, Burian J.3, Marek M.3, Honzátko J.4, Tomandl I.4, Kříž O.5, Janků I.6, Mareš V.7:
Contemporary State of Neutron Capture
Therapy in the Czech Republic. (Part 2)
|
60 |
Masopust J., Hosák L., Waberžinek G.1, Kunc P.1:
Cerebellar-olivar Atrophy with Dementia
|
64 |
Anders M.1, Roth J.2, Uhrová T.1, Židovská J.3, Vevera J.1, Doubek P.1:
Psychopathology of
Huntington’s Disease – Case-report
|
70 |
Junková E., Hadač J.:
A Combination of Epileptic and Psychogenically Conditioned
Paroxysms in a Child – Case-report with Diagnostic and Therapeutic Considerations
|
73 |
